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S U M M A R Y
Objectives: Insulin resistance (IR) affects sustained virological response (SVR) in chronic hepatitis C
(CHC). The aim of this study was to investigate the effect of adding metformin to peginterferon alfa-2a
and ribavirin on the efﬁcacy in patients with genotype 1 CHC and IR.
Methods: Ninety-eight patients with genotype 1 CHC and IR were randomized into the treatment group
(n = 49) and the control group (n = 49). Patients in the control group received peginterferon alfa-2a and
ribavirin, and patients in the treatment group received metformin in addition to peginterferon alfa-2a
and ribavirin. The rate of virological response, changes in the homeostasis model assessment of insulin
resistance (HOMA-IR) index, and the incidence of side effects were compared between the two groups.
Factors inﬂuencing the SVR were studied by multivariate analysis.
Results: The SVR rate of the treatment group was signiﬁcantly higher than that of the control group
(59.2%, 29/49 vs. 38.8%, 19/49; Chi-square = 4.083, p = 0.043). The HOMA-IR index of patients in the
treatment group was lower than that of patients in the control group at weeks 12, 24, and 48 of the
treatment period, and at week 24 of follow-up (3.00  0.65 vs. 3.50  0.72, 1.90  0.45 vs. 2.90  0.64,
1.75  0.40 vs. 2.74  0.48, and 1.60  0.35 vs. 2.60  0.55, respectively; t = 3.610, 8.947, 11.091, and 10.738,
respectively; p < 0.01). Diarrhea was more often seen in the treatment group (28.6%, 14/49 vs. 10.2%, 5/49;
Chi-square = 5.288, p = 0.021). In the multivariate logistic regression analysis, the independent factors
associated with SVR were treatment method (p = 0.009) and HOMA-IR <2 at week 24 (p = 0.011).
Conclusions: A combination of metformin, peginterferon alfa-2a, and ribavirin improved insulin
sensitivity and increased the SVR rate of patients with hepatitis C genotype 1 and IR, with a good safety
proﬁle.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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A combination of interferon (IFN) or peginterferon (PEG-IFN)
plus ribavirin is the recommended therapy for patients with
chronic hepatitis C (CHC). A sustained virological response (SVR) is
achieved in 40–54% of patients infected with hepatitis C virus
(HCV) genotype 1 treated with PEG-IFN plus ribavirin at approved
doses for 48 weeks.1 Host and viral factors inﬂuence the SVR rate to
combined IFN/ribavirin therapy. Insulin resistance (IR), ﬁbrosis,
and genotype are independent predictors of the response to
antiviral therapy in CHC patients treated with PEG-IFN plus
ribavirin.2 Other host factors associated with IR, such as increased
body mass index (BMI) and hepatocyte steatosis, have also been
observed to be associated with a poorer SVR rate.3 IR has been
implicated in the progression of ﬁbrosis4 and the development of
steatosis5 in CHC infection. In a previous study, we showed that the* Corresponding author. Tel.: +86 0451 86605614; fax: +86 0451 86605614.
E-mail address: lijiesun5234@yahoo.com.cn (L.-J. Sun).
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index was an independent factor for predicting the effect of
antiviral therapy.6 In another study, SVR was reported in 32.8% of
patients with genotype 1 and IR (HOMA-IR >2) vs. 60.5% of
patients with genotype 1 without IR,7 and these ﬁndings were
recently extended to non-responders with genotypes 2 and 3.8
These observations have led experts to suggest that managing IR
might improve the hepatitis treatment outcome. Weight reduction
and lifestyle modiﬁcations that include increased physical exertion
are effective methods for improving IR. Unfortunately, this can be
achieved or maintained by only a limited number of patients. In
consideration of accumulating clinical as well as laboratory
experimental evidence that IR is the key metabolic abnormality
in CHC, it has been proposed that treatment with insulin-sensitizing
agents might prove effective. Metformin is an oral biguanide, and is
one of the most widely prescribed therapeutic agents for the control
of type 2 diabetes. Metformin controls glucose levels by suppression
of hepatic glucose output, by increasing insulin-mediated glucose
disposal, and by decreasing fatty acid oxidation and the synthesis of
very-low-density lipoprotein.9 Romero-Go´mez et al. proved thatses. Published by Elsevier Ltd. All rights reserved.
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insulin sensitivity and SVR in female patients with CHC and IR.10
However, the effect of metformin treatment on IR affected by HCV
genotype 1 has not been shown histologically.
Because the relationship between improving IR and SVR in
patients with CHC has not been completely elucidated as yet, the
aim of this study was to investigate the effect of adding metformin
to PEG-IFN alfa-2a and ribavirin on the efﬁcacy in patients with
genotype 1 CHC and IR.
2. Methods
2.1. Study population
Eligible patients were positive for serum antibodies to HCV and
had detectable serum HCV RNA and compensated liver disease. All
patients were infected with HCV genotype 1, were aged 18 years or
older, had serum alanine aminotransferase (ALT) levels <2.5 times
the upper limit of normal, and had IR (HOMA-IR >2). Patients were
excluded if they had hepatitis A, B, D, or E, or HIV infection. Further
exclusion criteria included autoimmune disease, psychiatric
disease, symptomatic cardiac or cardiovascular diseases, alcohol
intake greater than 20 g daily, and the presence of drug abuse.
Patients were ineligible if they had received IFN and/or ribavirin
previously. The neutrophil count had to be at least 1.5  109/l,
platelet count >100  109/l, hemoglobin level >120 g/l in women
and >130 g/l in men, and serum creatinine levels <1.5 times the
upper limit of normal. Patients previously diagnosed as having
type 2 diabetes mellitus or who had fasting plasma glucose (FPG)
levels >7 mmol/l were also excluded. Decompensated liver
cirrhosis and hepatocellular carcinoma were excluded in all
patients by computed tomography (CT) and/or magnetic reso-
nance imaging (MRI), and/or elevated alpha-fetoprotein.
The trial was approved by the Ethics Committee of Harbin
University in accordance with the Declaration of Helsinki. Before
inclusion in this study, all patients were informed of its purpose,
nature, and duration, as well as the possible risks and beneﬁts of
the study intervention. All patients gave written informed consent
before enrolment.
2.2. Study design
This randomized, open-label clinical trial was conducted
between August 2007 and August 2008, at the Department of
Infectious Diseases, Second Afﬁliated Hospital, Harbin Medical
University, China. Using sealed envelopes with a 1:1 randomiza-
tion ratio, a total of 98 patients who fulﬁlled the inclusion criteria
were randomly assigned into the treatment group (n = 49) and the
control group (n = 49).
The patients in the control group received 180 mg PEG-IFN alfa-
2a (Pegasys; Hoffmann-La Roche, Basel, Switzerland) subcutane-
ously once a week plus daily ribavirin (1000 mg/day for weight
<75 kg, or 1200 mg/day for weight 75 kg) for 48 weeks. The
patients in the treatment group received metformin (Sino-American
Shanghai Squibb Pharmaceuticals Ltd) 500 mg three times daily for
48 weeks in addition to PEG-IFN alfa-2a and ribavirin. All subjects
were followed up for 24 weeks after the cessation of therapy.
Dosage reductions of PEG-IFN alfa-2a and ribavirin were
advised for managing neutropenia, thrombocytopenia, and ane-
mia. The PEG-IFN dose was modiﬁed by a 45-mg stepwise decrease
to enhance adherence. When the patient’s absolute neutrophil
count (ANC) fell below 0.75  109/l, the dose of PEG-IFN alfa-2a
was reduced to 135 or 90 mg per week; when the patient’s ANC fell
below 0.5  109/l, PEG-IFN alfa-2a was discontinued temporarily.
When the patient’s platelet count fell below 50  109/l, the dose of
PEG-IFN alfa-2a was reduced to 90 mg per week; when thepatient’s platelet count fell below 25  109/l, PEG-IFN alfa-2a was
discontinued temporarily. The dose of ribavirin was reduced by
200 mg/day when the patient’s hemoglobin concentration fell
below 100 g/l. Ribavirin was discontinued when the patient’s
hemoglobin concentration fell below 85 g/l. Patients could receive
PEG-IFN alfa-2a alone if ribavirin was stopped. Restoration of the
treatment was permitted if the laboratory abnormality improved.
2.3. Serum HCV RNA and HCV genotyping
Serum antibodies to HCV were detected by a third-generation
HCV ELISA (Ortho Diagnostic Systems, Raritan, NJ, USA). Serum
HCV RNA levels were measured by a quantitative RT-PCR assay
(Cobas Amplicor HCV Monitor 2.0; Roche Diagnostic Systems,
Branchburg, NJ, USA). The lower detection limit of the qualitative
assay is 100 copies/ml. The HCV genotype was determined by
restriction fragment length polymorphism of sequences ampliﬁed
in the 50 non-coding region.
2.4. Observation items
Each patient’s body weight and height were measured. BMI was
calculated as body weight in kilograms divided by the square of the
height in meters (kg/m2).
The levels of fasting blood triglycerides (TG), total cholesterol
(TC), and FPG were measured by Beckman automated biochemis-
try apparatus (Beckman Co., Fullerton, CA, USA).
Achievement of rapid virological response (RVR), complete
early virological response (cEVR), partial early virological response
(pEVR), end-of-treatment virological response (ETVR), and sus-
tained virological response (SVR) was observed. RVR was deﬁned
as undetectable serum HCV RNA after 4 weeks of combination
therapy. cEVR was deﬁned as HCV RNA negative at week 12, but no
RVR. pEVR was deﬁned as a 2 log10 drop in HCV RNA level from
baseline at week 12, but no RVR or cEVR. Patients with
undetectable virus at the end of treatment were considered to
have achieved an ETVR. Relapse was deﬁned as patients with
undetectable HCV RNA at the end of treatment and detectable HCV
RNA during follow-up. Only patients with undetectable virus at the
end of treatment and again 24 weeks after completion of treatment
were considered to have achieved an SVR.
For the determination of the level of fasting plasma insulin, on
an empty stomach, 3 ml venous blood was drawn from all patients.
The level of fasting plasma insulin was measured using a chemical
luminescence meter (Bayer Centaur, Tarry Town, NY, USA).
IR was estimated using the HOMA from fasting glucose and
insulin concentrations using the following formula: HOMA-
IR = (fasting plasma insulin (mIU/l)  FPG (mmol/l))/22.5.
Blood lactate levels were measured using a commercially
available kit (Immulite Diagnostic Products, Los Angeles, CA, USA).
Pretreatment and post-treatment liver biopsy specimens were
analyzed for ﬁbrosis on a scale of F0–F4 (F0, no ﬁbrosis; F1, portal
ﬁbrosis without septa; F2, portal ﬁbrosis with a few septa; F3,
numerous septa without cirrhosis; and F4, cirrhosis), and for
necroinﬂammatory activity on a scale of A0–A3 (A0, no histological
activity; A1, mild activity; A2, moderate activity; and A3, severe
activity). The degree of steatosis was further classiﬁed as grade 0 if
<5% of hepatocytes were involved, grade 1 if 5–33% of hepatocytes
were involved, grade 2 if 33–66% of hepatocytes were involved, and
grade 3 if >66% of hepatocytes were involved.11 All biopsies were
reviewed by a single pathologist unaware of patient identities or
treatment regimen.
The primary end-point was SVR. The secondary end-points
were: (1) viral clearance at weeks 4, 12, 24, and 48; (2) changes in
the HOMA-IR index and BMI at weeks 12, 24, and 48 of the
treatment phase, and at week 24 of the follow-up period.
Table 1
Comparison of patient characteristics between the treatment and control groups at
baseline
Treatment (n = 49) Control (n = 49)
Age, years 42  6 40  7
Sex, male/female 30/19 31/18
Total cholesterol, mmol/l 4.41  0.42 4.39  0.37
Triglycerides, mmol/l 1.37  0.21 1.42  0.22
Alanine aminotransferase, U/l 71  18 72  17
g-Glutamyltranspeptidase, U/l 82  12 79  11
HCV RNA, log copies/ml 6.5  0.6 6.4  0.5
BMI, kg/m2 28.2  2.8 28.0  2.9
Insulin level, mIU/l 14.35  3.58 14.10  3.34
HOMA-IR, mIUmmoll2 3.80  0.71 3.91  0.78
Fibrosis, F0–2/F3–4 34/15 35/14
Steatosis, G1/G2/G3 15/29/5 16/27/6
Activity, A1/A2 26/23 25/24
Results are mean  standard deviation or numbers. HCV, hepatitis C virus; RNA,
ribonucleic acid; BMI, body mass index; HOMA-IR, homeostasis model assessment of
insulin resistance; G, grade; F, ﬁbrosis; A, activity.
Note: by t-test, p > 0.05.
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laboratory tests at weeks 4, 8, 12, 24, and 48 of the treatment
phase, and at week 24 of the follow-up period. Serum glucose,
lactate, and ALT levels were monitored during treatment. All
adverse events were recorded.
2.5. Statistical analysis
The sample size estimation was based on the assumption that
metformin improving IR could increase the SVR rate in 28%.7 The
estimated sample size was 98 patients. All efﬁcacy analyses were
conducted on an intention-to-treat (ITT) basis and dropouts were
treated as failures.
The clinical, biochemical, and virological characteristics of the
patients were expressed as mean  standard deviation. The
Student’s t-test was used when necessary for statistical comparisons
of quantitative data, whereas the Chi-square test or Fisher’s exact test
was used when necessary for qualitative data. For all analyses, a p-
value of <0.05 was considered statistically signiﬁcant.
Multiple logistic regression analysis was used to identify factors
related to SVR. In the multivariate logistic regression model,
efﬁcacy of combination antiviral therapy (coded as 1, SVR; or 0,
without SVR) was deﬁned as the dependent variable, and several
factors (age, sex, baseline BMI, HCV RNA levels, ALT levels, TC
levels, TG levels, steatosis, ﬁbrosis, HOMA-IR index, treatment
method, the decline of HOMA-IR during treatment, and HOMA-IR
<2 at week 24) were deﬁned as independent variables. Variables
that achieved statistical signiﬁcance in the univariate analysis (p <
0.05) were subsequently included in the logistic regression
analysis. The selection of variables was based on a stepwise
regression analysis using a forward selection method. All analyses
were performed using SPSS statistical software package (version
10.0; Chicago, IL, USA).
3. Results
3.1. Comparison of patient characteristics in the two groups at
baseline
A total of 98 patients were enrolled in this study. In the
treatment group, two patients withdrew from the study because of
adverse effects, two patients were lost to follow-up, and 45
patients completed treatment and follow-up. In the control group,
two patients withdrew from the study because of adverse effects,
one patient was lost to follow-up, and 46 patients completed
treatment and follow-up. No signiﬁcant differences were observed
between patients in the treatment group and in the control group
with regard to gender, age, HCV RNA levels, TC levels, TG levels,
serum ALT levels, HOMA-IR index, or histological parameters
(p > 0.05) (Table 1).Table 2
Comparison of virological response rates between the treatment and control groups
Treatment (n = 49) 
On-treatment virological response 
RVR 20.4% (10/49) 
cEVR 51.0% (25/49) 
pEVR 14.3% (7/49) 
No RVR or EVR 14.3% (7/49) 
ETVR 67.3% (33/49) 
Relapse rate 12.1% (4/33) 
SVR 59.2% (29/49) 
RVR, rapid virological response; cEVR, complete early virological response; pEVR, par
sustained virological response.3.2. Comparison of virological response rates between the two patient
groups
In the ITT analysis, there was a signiﬁcant difference in the on-
treatment virological response between the two groups (Chi-
square = 18.552, p < 0.001). Patients in the treatment group had a
signiﬁcantly higher cEVR rate (51.0%, 25/49 vs. 16.3%, 8/49; Chi-
square = 13.024, p < 0.001) and lower pEVR rate (14.3%, 7/49 vs.
49.0%, 24/49; Chi-square = 13.636, p < 0.001) than patients in the
control group; patients in the treatment group had a signiﬁcantly
higher ETVR rate than patients in the control group (67.3%, 33/49
vs. 44.9%, 22/49; Chi-square = 5.014, p = 0.025); patients in the
treatment group had a signiﬁcantly higher SVR rate than patients
in the control group (59.2%, 29/49 vs. 38.8%, 19/49; Chi-
square = 4.083, p = 0.043) (Table 2).
3.3. Comparison of HOMA-IR index and BMI between the two patient
groups
The mean HOMA-IR index in the treatment group at weeks 12,
24, and 48 of the treatment phase, and week 24 of the follow-up
period was 3.00  0.65, 1.90  0.45, 1.75  0.40, and 1.60  0.35,
respectively, which was signiﬁcantly lower than the control group
(3.50  0.72, 2.90  0.64, 2.74  0.48, and 2.60  0.55, respectively;
t = 3.610, 8.947, 11.091, and 10.738, respectively; p < 0.01) (Figure 1).
The BMI decreased in both groups after treatment. The mean
BMI in the treatment group at weeks 12, 24, and 48 of the
treatment phase, and week 24 of the follow-up period was
28.0  3.0, 27.8  3.1, 27.1  3.0, and 26.8  2.9 kg/m2, respectively;
while it was 27.9  3.1, 27.7  3.0, 27.4  3.2, and 27.0  2.8 kg/m2,Control (n = 49) p-Value
Chi-square = 18.552, p < 0.001
16.3% (8/49)
16.3% (8/49) Chi-square = 13.204, p < 0.001
49.0% (24/49) Chi-square = 13.636, p < 0.001
18.4% (9/49)
44.9% (22/49) Chi-square = 5.014, p = 0.025
13.6% (3/22) Fisher’s exact test, p = 1.000
38.8% (19/49) Chi-square = 4.083, p = 0.043
tial early virological response; ETVR, end of treatment virological response; SVR,
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Figure 1. Changes in the patient HOMA-IR index in the treatment and control groups.
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Figure 2. Comparison of the degree of steatosis before and after treatment in the
treatment group.
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Figure 3. Comparison of the degree of steatosis before and after treatment in the
control group.
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(t = 0.164, 0.165, 0.495, 0.367, respectively; p > 0.05).
3.4. The relationship between SVR and HOMA-IR index at week 24
At week 24, there were 31 patients (25 in the treatment group
and six in the control group) with a HOMA-IR index of <2. A
HOMA-IR index <2 at week 24 was more often seen in the
treatment group than in the control group (51.0%, 25/49 vs. 12.2%
6/49; Chi-square = 17.003, p < 0.001). Twenty-four of 31 patients
with a HOMA-IR index <2 at week 24 achieved SVR, whereas 24 of
67 patients with a HOMA-IR index 2 achieved SVR. The SVR rate
of patients with a HOMA-IR index < 2 was signiﬁcantly higher than
that of patients with a HOMA-IR index 2 (77.4% vs. 35.8%, Chi-
square = 14.676, p < 0.001).
3.5. Comparison of side effects between the two patient groups
There was no serious adverse event during treatment with
metformin, PEG-IFN alfa-2a, and ribavirin. Diarrhea was more
often seen in the treatment group (28.6%, 14/49 vs. 10.2%, 5/49;
Chi-square = 5.288, p = 0.021). The diarrhea was mild, well
tolerated, and did not lead to any withdrawals from the trial.
No patient in the treatment group developed lactic acidosis, or
hyperlactatemia, or hypoglycemia (Table 3).
3.6. Comparison of the degree of liver steatosis before and after
treatment between the two patient groups
At the end of treatment, a liver biopsy was performed in 17
patients (34.7%) in the treatment group and 15 patients (30.6%) in
the control group. The other patients refused a liver biopsy. The
degree of steatosis was improved in the treatment group compared
to baseline (grade 1/2/3: 15/29/5 vs. 11/5/1, Chi-square = 6.155,
p = 0.046) (Figure 2). There was no difference in distribution of the
degree of steatosis in the control group before and after treatment
(grade 1/2/3: 16/27/6 vs. 6/7/2, Chi-square = 0.345, p = 0.842)
(Figure 3).Table 3
Comparison of side effects between the treatment and control groups
Treatment
(n = 49)
Control
(n = 49)
p-Value
Neutropenia (neutrophils <0.5  109/l) 6 7 p = 1.000a
Thrombocytopenia (platelets <50  109/l) 3 2 p = 1.000a
Anemia (hemoglobin <85 g/l) 1 2 p = 1.000a
Hypertransaminasemia 2 1 p = 1.000a
Diarrhea 14 5 p = 0.021b
Leading to withdrawal 2 2 p = 1.000a
a By Fisher’s exact test.
b By Chi-square test; Chi-square = 5.288.3.7. Predictive factors associated with SVR in CHC patients
Predictive factors associated with SVR in CHC patients were
studied. In the univariate analysis, HCV RNA levels (p = 0.007),
ﬁbrosis (p = 0.021), treatment method (p = 0.043), baseline HOMA-
IR (p = 0.008), the decline of HOMA-IR during treatment
(p < 0.001), and HOMA-IR < 2 at week 24 (p < 0.001) were
associated with SVR (Table 4). In the multivariate logistic
regression analysis, the independent factors associated with SVR
were treatment method (p = 0.009) and HOMA-IR <2 at week 24
(p = 0.011) (Table 5).
4. Discussion
Our previous study demonstrated that IR and hyperinsulinemia
in patients with CHC often led to hepatic steatosis and adversely
affected the virological response rates to anti-HCV therapy.6 IR is
associated with the progression of ﬁbrosis in CHC, and an increased
HOMA-IR index has been shown to be an independent predictor of
treatment failure in patients treated with PEG-IFN and ribavirin.7
Because IR can be modiﬁed by changes in lifestyle habits and by
insulin-sensitizer drugs, this could be a potential target for
treatment in CHC. Pioglitazone and metformin were tested in
HCV genotype 1 and IR patients with promising results and a wide
safety proﬁle.10,12 No prospective trials of relevant size have been
published to date to prove the efﬁcacy of a therapeutic
intervention aimed at improving IR in SVR. HCV proteins promote
insulin receptor substrate 1 degradation by several mechanisms,
including oxidative stress, down-regulation of peroxisome pro-
liferator-activated receptor (PPAR), and enhancing tumor necrosis
factor (TNF) production in a genotype-dependent manner.13 Thus,
metformin could be useful in the management of this comorbidity
because of its ability to increase the binding of insulin to its
receptors and to increase phosphorylation, as well as the tyrosine
Table 4
Univariate analysis of associations between SVR and inﬂuential factors in CHC patients
Variable Patients with SVR
(n = 48)
Patients without SVR
(n = 50)
p-Value
Sex, male/female 32/16 29/21 Chi-square = 0.783, p = 0.376
HCV RNA level, log copies/ml 5.8  0.9 6.8  1.0 t = 5.206, p = 0.007
Alanine aminotransferase level, U/l 75  18 74  17 t = 0.848, p = 0.315
Treatment method, metformin/control 29/19 20/30 Chi-square = 4.083, p = 0.043
Age, years 41  8 40  7 t = 0.657, p = 0.525
BMI, kg/m2 28.8  2.1 29.0  2.5 t = 0.173, p = 0.852
Baseline HOMA-IR index, mIUmmoll2 3.48  0.49 4.24  0.92 t = 5.109, p = 0.008
Total cholesterol, mmol/l 4.35  0.32 4.41  0.35 t = 0.889, p = 0.302
Triglycerides, mmol/l 1.38  0.24 1.41  0.27 t = 0.582, p = 0.756
The decline of HOMA-IR during treatment 1.65  0.32 0.81  0.15 t = 16.635, p < 0.001
HOMA-IR index <2 at week 24, yes/no 24/24 7/43 Chi-square = 14.676, p < 0.001
Fibrosis, F0–2/F3–4 39/9 30/20 Chi-square = 5.308, p = 0.021
Steatosis, G1/G2/G3 18/27/3 13/29/8 Chi-square = 3.111, p = 0.211
Results are mean  standard deviation or numbers. SVR, sustained virological response; CHC, chronic hepatitis C; HCV, hepatitis C virus; RNA, ribonucleic acid; BMI, body mass
index; HOMA-IR, homeostasis model assessment of insulin resistance; F, ﬁbrosis; G, grade.
Table 5
Multivariate logistic regression analysis of the associations between SVR and inﬂuential factors in CHC patients
Variable Coefﬁcient Chi-square OR (95% CI) p-Value
Baseline HOMA-IR index 1.550 3.028 4.711 (0.795–5.478) 0.077
HOMA-IR index <2 at week 24 1.339 4.859 3.815 (2.011–6.007) 0.011
Treatment method 2.354 9.685 10.528 (4.583–15.135) 0.009
HCV RNA level 1.325 2.958 3.762 (0.939–5.798) 0.179
Fibrosis 1.006 2.493 0.366 (0.149–1.001) 0.289
SVR, sustained virological response; CHC, chronic hepatitis C; OR, odds ratio; CI, conﬁdence interval; HOMA-IR, homeostasis model assessment of insulin resistance; HCV,
hepatitis C virus; RNA, ribonucleic acid.
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whether the addition of metformin to the standard of care could
improve SVR in treatment-naı¨ve patients with HCV genotype 1 and
IR.
Metformin is an oral biguanide that lowers blood glucose and
insulin secretion and improves the individual’s lipid proﬁle, mainly
because of suppression of hepatic glucose output and increased
glucose uptake in skeletal muscle.15 In our study, the mean HOMA-
IR index from week 12 in the treatment group was signiﬁcantly
lower than that of the control group, and a HOMA-IR index <2 at
week 24 was more often seen in the treatment group, which
suggests that the use of metformin is associated with an
improvement in IR. Khattab et al. proved that a combination of
pioglitazone, PEG-IFN alfa-2b, and ribavirin improved insulin
sensitivity and increased the SVR rate by improving the RVR rate in
patients with hepatitis C genotype 1 and IR.12 However, in this
study, the two groups had similar RVR rates. Patients in the
treatment group had a signiﬁcantly higher cEVR rate and lower
pEVR rate than patients in the control group. The higher SVR rate in
the metformin group was associated with a higher cEVR rate. The
improvement in early virological response rates was consistent
with the decrease in HOMA-IR index at week 12.
Deciding on whether to start the antiviral treatment together
with the insulin sensitizer, or only once the HOMA-IR score has
decreased to a level predicting a sufﬁcient SVR rate, is still a
challenge.16 Because of the delayed effect of an insulin sensitizer
such as pioglitazone on IR and steatosis, commencing administra-
tion concomitantly with the antiviral therapy may be untimely.17
In this study, we found that adding metformin to the standard
antiviral treatment improved SVR. Moreover, the optimal HOMA-
IR score to be reached to predict a satisfactory SVR was HOMA-IR
<2 at week 24. The sequential administration of antiviral
treatment before managing IR by weight loss or insulin sensitizers
seems a reasonable approach from our ﬁndings.
The results of several pilot studies have suggested that
treatment with metformin or pioglitazone improves ALT levels,IR, and hepatic steatosis in patients with non-alcoholic steatohe-
patitis.18,19 Whether insulin-sensitizing drugs improve the liver
steatosis by the HCV core protein has not been examined fully. In
our study, steatosis was improved in patients treated with
metformin, although the number of patients with post-treatment
biopsies was relatively small.
In the current study, serum glucose, lactate, and ALT levels were
monitored during treatment. No patients developed lactic acidosis,
or hyperlactatemia, or serious hepatotoxicity. Metformin was
associated with mild diarrhea, which was well tolerated, and no
patient withdrew from the study because of this adverse event.
Thus, metformin used together with PEG-IFN alfa-2a and ribavirin
in the treatment of hepatitis C appears to be safe. However, it is
important to pay attention to the possible interactions of
metformin with other drugs, especially those taken for psychiatric
comorbidities.
The small number of patients, the unblinded nature of the
study, and the lack of a placebo group were major drawbacks of
this investigation. In addition, a post-treatment liver biopsy could
not be performed in a certain proportion of patients and paired
liver histology was available for only one-third of patients, so the
impact of histological variables such as liver steatosis could not be
assessed deﬁnitively.
In conclusion, our study indicates that a combination of
metformin, PEG-IFN alfa-2a, and ribavirin improves insulin
sensitivity and increases the SVR rate in patients with hepatitis
C genotype 1 and IR, with a good safety proﬁle. A multicenter,
randomized and controlled trial is needed to further validate these
conclusions.
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